INCY vs. UHS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at INCY and UHS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | INCY | UHS |
|---|---|---|
| Company Name | Incyte Corporation | Universal Health Services, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 16.96 billion USD | 13.19 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | November 4, 1993 | July 9, 1981 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of INCY and UHS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| 5-Day Price Return | 3.53% | 3.07% |
| 13-Week Price Return | 26.88% | 12.31% |
| 26-Week Price Return | 43.44% | 10.29% |
| 52-Week Price Return | 28.42% | -7.48% |
| Month-to-Date Return | 2.41% | 1.37% |
| Year-to-Date Return | 25.74% | 15.51% |
| 10-Day Avg. Volume | 1.48M | 0.66M |
| 3-Month Avg. Volume | 1.84M | 0.85M |
| 3-Month Volatility | 32.56% | 28.09% |
| Beta | 0.82 | 1.29 |
Profitability
Return on Equity (TTM)
INCY
24.09%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 24.09% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
UHS
18.62%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
In the upper quartile for the Health Care Providers & Services industry, UHS’s Return on Equity of 18.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
INCY
18.99%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 18.99% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
UHS
7.66%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
A Net Profit Margin of 7.66% places UHS in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
INCY
25.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 25.80% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
UHS
10.99%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
An Operating Profit Margin of 10.99% places UHS in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Return on Equity (TTM) | 24.09% | 18.62% |
| Return on Assets (TTM) | 15.81% | 8.60% |
| Net Profit Margin (TTM) | 18.99% | 7.66% |
| Operating Profit Margin (TTM) | 25.80% | 10.99% |
| Gross Profit Margin (TTM) | 93.41% | -- |
Financial Strength
Current Ratio (MRQ)
INCY
2.85
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
INCY’s Current Ratio of 2.85 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
UHS
1.29
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
UHS’s Current Ratio of 1.29 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
INCY
0.01
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
UHS
0.65
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
UHS’s Debt-to-Equity Ratio of 0.65 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
UHS
9.05
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
UHS’s Interest Coverage Ratio of 9.05 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Current Ratio (MRQ) | 2.85 | 1.29 |
| Quick Ratio (MRQ) | 2.55 | 1.19 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.65 |
| Interest Coverage Ratio (TTM) | 6.86 | 9.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
UHS
0.40%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Yield of 0.40% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
UHS
4.19%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
UHS’s Dividend Payout Ratio of 4.19% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.40% |
| Dividend Payout Ratio (TTM) | 0.00% | 4.19% |
Valuation
Price-to-Earnings Ratio (TTM)
INCY
19.39
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
INCY’s P/E Ratio of 19.39 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
UHS
10.44
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
In the lower quartile for the Health Care Providers & Services industry, UHS’s P/E Ratio of 10.44 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
INCY
3.68
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 3.68 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
UHS
0.80
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
UHS’s P/S Ratio of 0.80 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
INCY
3.16
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
INCY’s P/B Ratio of 3.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
UHS
1.66
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
UHS’s P/B Ratio of 1.66 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | INCY | UHS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 19.39 | 10.44 |
| Price-to-Sales Ratio (TTM) | 3.68 | 0.80 |
| Price-to-Book Ratio (MRQ) | 3.16 | 1.66 |
| Price-to-Free Cash Flow Ratio (TTM) | 17.63 | 14.61 |